|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C6orf62 |
Gene summary for C6ORF62 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C6orf62 | Gene ID | 81688 |
| Gene name | chromosome 6 open reading frame 62 | |
| Gene Alias | Nbla00237 | |
| Cytomap | 6p22.3 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | A0A024R026 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 81688 | C6orf62 | LZE2T | Human | Esophagus | ESCC | 7.56e-03 | 2.07e-01 | 0.082 |
| 81688 | C6orf62 | LZE4T | Human | Esophagus | ESCC | 1.82e-15 | 4.96e-02 | 0.0811 |
| 81688 | C6orf62 | LZE5T | Human | Esophagus | ESCC | 5.26e-04 | 3.49e-01 | 0.0514 |
| 81688 | C6orf62 | LZE7T | Human | Esophagus | ESCC | 2.69e-06 | 6.33e-01 | 0.0667 |
| 81688 | C6orf62 | LZE8T | Human | Esophagus | ESCC | 5.38e-07 | 1.08e-01 | 0.067 |
| 81688 | C6orf62 | LZE21D1 | Human | Esophagus | HGIN | 3.27e-05 | 7.17e-02 | 0.0632 |
| 81688 | C6orf62 | LZE22D1 | Human | Esophagus | HGIN | 5.37e-05 | 8.48e-02 | 0.0595 |
| 81688 | C6orf62 | LZE22T | Human | Esophagus | ESCC | 2.13e-06 | 1.31e-01 | 0.068 |
| 81688 | C6orf62 | LZE24T | Human | Esophagus | ESCC | 2.72e-06 | 4.06e-01 | 0.0596 |
| 81688 | C6orf62 | P1T-E | Human | Esophagus | ESCC | 1.33e-08 | 3.55e-01 | 0.0875 |
| 81688 | C6orf62 | P2T-E | Human | Esophagus | ESCC | 3.72e-27 | 5.48e-01 | 0.1177 |
| 81688 | C6orf62 | P4T-E | Human | Esophagus | ESCC | 4.30e-24 | 1.84e-01 | 0.1323 |
| 81688 | C6orf62 | P5T-E | Human | Esophagus | ESCC | 1.89e-14 | -2.44e-02 | 0.1327 |
| 81688 | C6orf62 | P8T-E | Human | Esophagus | ESCC | 4.44e-22 | 3.54e-01 | 0.0889 |
| 81688 | C6orf62 | P9T-E | Human | Esophagus | ESCC | 1.68e-12 | 3.63e-01 | 0.1131 |
| 81688 | C6orf62 | P10T-E | Human | Esophagus | ESCC | 1.11e-26 | 4.83e-01 | 0.116 |
| 81688 | C6orf62 | P11T-E | Human | Esophagus | ESCC | 4.51e-06 | 4.47e-01 | 0.1426 |
| 81688 | C6orf62 | P12T-E | Human | Esophagus | ESCC | 3.32e-21 | 2.34e-01 | 0.1122 |
| 81688 | C6orf62 | P15T-E | Human | Esophagus | ESCC | 5.73e-18 | 2.59e-01 | 0.1149 |
| 81688 | C6orf62 | P16T-E | Human | Esophagus | ESCC | 7.26e-18 | 2.08e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C6orf62 | SNV | Missense_Mutation | c.151N>A | p.Glu51Lys | p.E51K | Q9GZU0 | protein_coding | deleterious(0.04) | probably_damaging(0.981) | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| C6orf62 | SNV | Missense_Mutation | c.568C>G | p.Pro190Ala | p.P190A | Q9GZU0 | protein_coding | tolerated(0.13) | possibly_damaging(0.508) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR | |
| C6orf62 | SNV | Missense_Mutation | c.151N>A | p.Glu51Lys | p.E51K | Q9GZU0 | protein_coding | deleterious(0.04) | probably_damaging(0.981) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| C6orf62 | SNV | Missense_Mutation | novel | c.503N>T | p.Gly168Val | p.G168V | Q9GZU0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-JW-AAVH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| C6orf62 | SNV | Missense_Mutation | novel | c.205N>G | p.Lys69Glu | p.K69E | Q9GZU0 | protein_coding | tolerated(0.31) | benign(0.133) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| C6orf62 | SNV | Missense_Mutation | novel | c.287N>A | p.Arg96Gln | p.R96Q | Q9GZU0 | protein_coding | tolerated(0.15) | probably_damaging(0.947) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| C6orf62 | SNV | Missense_Mutation | rs746089400 | c.671G>A | p.Arg224His | p.R224H | Q9GZU0 | protein_coding | tolerated_low_confidence(0.17) | benign(0) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| C6orf62 | insertion | Frame_Shift_Ins | novel | c.69_70insA | p.Glu24ArgfsTer5 | p.E24Rfs*5 | Q9GZU0 | protein_coding | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | ||
| C6orf62 | SNV | Missense_Mutation | c.353N>A | p.Arg118Gln | p.R118Q | Q9GZU0 | protein_coding | tolerated(0.08) | benign(0.003) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| C6orf62 | SNV | Missense_Mutation | novel | c.498G>T | p.Lys166Asn | p.K166N | Q9GZU0 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |